American Heart Journal
Volume 160, Issue 2 , Pages 209-214 , August 2010

A review of dyspnea in acute heart failure syndromes

  • Ryenn L. West, BS

      Affiliations

    • Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC
    • ,
  • Adrian F. Hernandez, MD, MHS

      Affiliations

    • Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC
    • Corresponding Author InformationReprint requests: Adrian F. Hernandez, MD, MHS, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715.
    • ,
  • Christopher M. O'Connor, MD

      Affiliations

    • Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC
    • ,
  • Randall C. Starling, MD, MPH

      Affiliations

    • Cleveland Clinic, Cleveland, OH
    • ,
  • Robert M. Califf, MD

      Affiliations

    • Duke Translational Medicine Institute, Duke University School of Medicine, Durham, NC

Received 18 April 2010 ,Accepted 15 May 2010.

References 

  1. Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112:3958–3968
  2. American Thoracic Society. Dyspnea. Mechanisms, assessment, and management: a consensus statement. Am J Respir Crit Care Med. 1999;159:321–340
  3. Manning HL, Scwartzstein RM. Pathophysiology of dyspnea. N Engl J Med. 1995;333:1547–1552
  4. Ambrosino N, Serradori M. Determining the cause of dyspnoea: linguistic and biological descriptors. Chron Respir Dis. 2006;3:117–122
  5. Parshall MB, Welsh JD, Brockopp DY, et al. Reliability and validity of dyspnea sensory quality descriptors in heart failure patients treated in an emergency department. Heart Lung. 2001;30:57–65
  6. Allen LA, Hernandez AF, O'Connor CM, et al. End points for clinical trials in acute heart failure syndromes. J Am Coll Cardiol. 2009;53:2248–2258
  7. Hajiro T, Nishimura K, Tsukino M, et al. Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med. 1998;158:1185–1189
  8. Cullen DL, Rodak B. Clinical utility of measures of breathlessness. Respir Care. 2002;47:986–993
  9. Teerlink JR. Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure. Am Heart J. 2003;145:S26–S33
  10. Boni E, Bezzi M, Carminati L, et al. Expiratory flow limitation is associated with orthopnea and reversed by vasodilators and diuretics in left heart failure. Chest. 2005;128:1050–1057
  11. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407–415
  12. Karras DJ, Sammon ME, Terregino CA, et al. Clinically meaningful changes in quantitative measures of asthma severity. Acad Emerg Med. 2000;7:327–334
  13. Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation. 2000;102:2222–2227
  14. Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531–1540
  15. Torre-Amione G, Young JB, Colucci WS, et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2003;42:140–147
  16. Allen LA, Metra M, Milo-Cotter O, et al. Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF). J Card Fail. 2008;14:777–784
  17. Ander DS, Aisiku IP, Ratcliff JJ, et al. Measuring the dyspnea of decompensated heart failure with a visual analog scale: how much improvement is meaningful?. Congest Heart Fail. 2004;10:188–191
  18. Kupferberg DH, Kaplan RM, Slymen DJ, et al. Minimal clinically important difference for the UCSD Shortness of Breath Questionnaire. J Cardiopulm Rehabil. 2005;25:370–377
  19. Witek TJ, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J. 2003;21:267–272
  20. McMurray JJ, Stewart S. The burden of heart failure. Eur Heart J. 2002;2:D50–D58
  21. Mebazaa A, Pang PS, Tavares M, et al. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J. 2009;[Epub ahead of print]
  22. Pang PS, Cleland JG, Teerlink JR, et al. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur Heart J. 2008;29:816–824
  23. Hernandez AF, Connor CM, Starling RC, et al. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J. 2009;157:271–277

PII: S0002-8703(10)00426-6

doi: 10.1016/j.ahj.2010.05.020

American Heart Journal
Volume 160, Issue 2 , Pages 209-214 , August 2010

Article Tools